Outcome of the Meeting of the Board of Directors of Welcure Drugs and Pharmaceuticals Limited held today i.e. Saturday, December 06, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Welcure Drugs & Pharmaceuticals, at its meeting on December 6, 2025, reviewed four previously announced transactions and decided to abort or modify most of them. The Letter of Intent for equity investment from Telexcell Trade PTE LTD (Singapore) stands closed, as parties could not agree on terms. The proposed Agro-Pharma Research Laboratory and the related plan to raise funds via QIP (Qualified Institutions Placement) have been shelved. Export-sourcing orders worth ₹299.91 crore were not executed as exports — instead, the same goods were sold in the Indian domestic market to the same parties, and revenue has been booked accordingly. The ₹517 crore third-party sourcing and procurement mandate with Fortune Sagar Impex Company Limited (Thailand) has also been discontinued and will not be pursued further.
This is a significantly negative disclosure for shareholders — deals collectively worth over ₹800 crore that had been announced over the past several months have either been aborted or substantially altered, which may weigh on the stock price and erode investor confidence in the company's announced growth plans.